Nabriva Therapeutics plc - NBRV STOCK NEWS

Nabriva Therapeutics (NASDAQ: NBRV) has granted a stock option for 100,000 ordinary shares to newly appointed General Counsel, Christopher Naftzger. This inducement grant was effective on September 30, 2021, with an exercise price of $1.19 per share, matching the closing share price on that date. The option has a 10-year term, vesting 25% annually over four years, contingent on Naftzger’s continued employment. This decision aligns with Nasdaq’s inducement grant exception, aimed at enhancing employee compensation.

Nabriva Therapeutics (NASDAQ: NBRV) announced the appointment of Dr. Christine Guico-Pabia as Chief Medical Officer effective October 1, 2021. Dr. Guico-Pabia brings over 30 years of global biopharmaceutical experience, including leadership roles at major pharmaceutical companies. Nabriva CEO Ted Schroeder expressed confidence in her ability to support the company’s clinical initiatives and drive development of innovative therapies addressing antibiotic resistance. Nabriva is known for its anti-infective agents and received FDA approval for XENLETA, along with ongoing developments for CONTEPO.

Nabriva Therapeutics (NASDAQ: NBRV) announced the presentation of data at the IDWeek 2021, scheduled from September 29 to October 3, 2021. The company and its collaborators will focus on the efficacy of lefamulin against Staphylococcus aureus in children with cystic fibrosis. This data will be part of a poster presentation titled “In Vitro Activity of Lefamulin against Staphylococcus aureus isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis.” Nabriva is known for its anti-infective agents, particularly the first pleuromutilin antibiotic, XENLETA, for community-acquired bacterial pneumonia.

Nabriva Therapeutics has partnered with Vizient to enhance the accessibility of XENLETA, a treatment for community-acquired bacterial pneumonia (CABP), across Vizient's extensive hospital network. This agreement is significant given that over half of U.S. hospitals are Vizient members, potentially impacting millions annually diagnosed with CABP. XENLETA offers a short-course, monotherapy option, addressing unmet medical needs, particularly in patients at risk from traditional treatments. This partnership is expected to improve patient outcomes and lower healthcare costs.

Nabriva Therapeutics (NASDAQ: NBRV) has announced that its partner, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd., received approval to market oral and IV formulations of XENLETA (lefamulin) for treating community-acquired pneumonia (CAP) in adults in Taiwan. This follows Nabriva's agreement with Sumitomo in May 2021 for the commercialization rights of lefamulin in the greater China region. The launch date for XENLETA in Taiwan has not yet been determined.

Nabriva Therapeutics (NASDAQ: NBRV) announced the granting of non-statutory stock options for 32,130 ordinary shares to three new employees as part of their compensation package. The stock options, effective August 31, 2021, have an exercise price of $1.06 per share, matching the closing price on the grant date. Each option has a 10-year term and vests over four years, contingent upon the employees' continued service. This grant follows Nasdaq's inducement grant exception and reflects Nabriva's commitment to attract talent in the biopharmaceutical sector.

Nabriva Therapeutics (NASDAQ: NBRV) announced that CEO Ted Schroeder will present a company overview at the H.C. Wainwright 23rd Annual Virtual Global Investment Conference. The presentation will be available on-demand starting September 13, 2021, at 7:00 A.M. (ET). Interested parties can access it via the 'Investors' section of the company's website under 'Events and Presentations'. Nabriva is known for its innovative anti-infective agents, including XENLETA® and CONTEPO™, aimed at treating serious infections.

Nabriva Therapeutics reported revenues of $8.2 million for Q2 2021, a substantial increase from $0.5 million in Q2 2020, primarily due to the launch of its SIVEXTRO National Drug Code (NDC). The company announced positive Phase 3 trial results for lefamulin in China, with commercial rights assigned to Sumitomo Pharmaceuticals. A renegotiated loan agreement has extended cash runway into Q1 2022, supporting operations. However, net loss decreased to $11.8 million compared to $15.4 million in the prior year, indicating improved financial management amid continued challenges.

Nabriva Therapeutics (NASDAQ: NBRV) announced on August 3, 2021, the granting of non-statutory stock options to three new employees. The stock options total 10,500 shares with an exercise price of $1.10, matching the closing price on the grant date, July 30, 2021. Each option has a 10-year term, vesting over four years based on continued service. The grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of the new hire compensation. Nabriva focuses on developing anti-infective agents and has received FDA approval for XENLETA®.